POLE and uterine carcinosarcoma: Potential of an immune checkpoint inhibitor as a promising targeted agent was also shown in a uterine carcinosarcoma patient harboring POLE mutation [43], reported to occur in about 2–4% of uterine carcinosarcomas [39–41].